VECTA TB-1000 is a patented, unique sequence derivative of a protein called Thymosin Beta-4 (TB-4) which is naturally present in all mammalian bodies. TB-1000 extracts only the most beneficial amino acids from the complete 43 amino-acid chain of Thymosin Beta-4.
TB-1000's patented and unique sequence allows for multiple functional benefits in Endurance Horses, Thoroughbreds and Racing Camels including ;
Of the many unique and beneficial functions of TB-1000, the activation of Angiogenesis is the most beneficial to all Endurance Horses, Thoroughbreds and Racing Camels when administered Intravenously. Angiogenesis is the production of new blood vessels from already existing vessels in blood. TB-1000 activates this process through the proliferation and migration of endothelial cells and reduces heart rates through a more efficient distribution of red cells, meaning the heart does not have to pump at a higher ratein order for the cells to reach muscle tissues required for peak performance.
The G-actin binding site is what promotes angiogenesis through the application of TB-4. The unique chain amino acid chain derivative contains the entire actin binding domain. This sequence has the ability to duplicate the activity of the intact molecule and block adhesion to TB-4. Actin has been proven to enhance angiogenesis and in ex vivo vessel sprouting assay. When added together with TB-4, instead of increasing further sprouting activity, reduced activity was observed . This supplies VECTA TB-1000 a significant benefit over other Thymosin Beta-4 based products that contain the complete 43 chain amino acid sequence.
The above image and accompanying bar graph demonstrate the activation of angiogenesis, forming new blood vessels (aortic sprouting) using four different Thymosin Beta-4 amino acid sequences, with VECTA TB-1000 being the bottom right image. As clearly indicated, VECTA TB-1000 provides the highest level of new blood vessel formation and when given IV, provides the greatest benefits for Endurance Horses and Racing Camels when compared to any other Thymosin Beta-4 based peptide (disregarding the claims made by other companies claiming to sell TB-1000) .
In recent times, recorded data have seen horses heart rates reduce anywhere between 4 – 10 beats per minute before and after competition. These effects are due to the angiogenesis process taking place and allowing for significantly more efficient blood distribution by the heart. Further recent data has shown clear improvement in blood analysis and amino-acid profiles in the body. These applicable benefits provide unparalleled performance benefits for Endurance Horses and Racing Camels.
Angiogenesis is also an important factor in wound healing. During wound healing, angiogenic capillary sprouts invade the fibrin/fibronectin-rich wound clot and within days and are organized into a micro vascular network throughout the granulation tissue. This provides accellerated and more effective wound healing.
Thymosin Beta-4 is also found in wound fluid. Platelets are the first cell to arrive at a wound site following an injury. It has been observed that increases of TB-4 increases a deposition of well organized collagen. This additional collagen in TB-4 treated wounds may explain the increase in contraction, may also affect the tensile strength of the wound .
Histological sections of 7 day wounds showing collagen deposition/accumulation.
Masson's trichrome staining shows collagen in blue and endothelial cells in red. (a) Low magnification view of a control wound treated with saline. (b, c) Low magnification views of wounds where T4 was injected intraperitoneally (b) or applied topically (a). Boxed areas are the location of the higher magnification fields (d–f ). Arrows indicate the edges of the original wound. (d) Control wound at higher magnification showing baseline collagen accumulation. Treatment intraperitoneally (e) or (f) topically resulted in enhanced collagen production/accumulation compared with wounds treated with saline. Scale bar: 1 m.
TB-1000 is effective in mast cell exocytosis . As mast cells contain androgen receptors, these components are directed out of the cell membrane and into the extracellular space. It is this vlaidation that explains the lean muscle growth that has been experienced from using TB-1000.
In addition to wound healing, angiogenesis and other biological activities, the unique and patented sequence of TB-1000 has been shown to align itself with a critical area of the Inhibitory Factor 1 (IF1). By binding to the both the alpha and beta subunits of Adenosin Tri-Phosphate synthase (ATP). This data suggests the intriguing possibility that TB-1000 is a mimicking agent of extracellular IF1 .
TB-1000 is completely safe and complies with the FEI rules and regulations.
Scientific Reference Data:
. Biological activities of thymosin B-4 defined by active
sites in short peptide sequences
Gabriel Sosne,*,1 Ping Qiu,† Allan L. Goldstein,† and Michelle Wheater‡
. The actin binding site on thymosin β-4 promotes angiogenesis
D. Philp,* T. Huff,. Y. S. Gho,. E. Hannappel,. and H. K. Kleinman*
. Thymosin B-4 Accelerates Wound Healing
Katherine M. Malinda, Gurmel S. Sidhu,* Haresh Mani,* Krishna Banaudha,* Radha K. Maheshwari,*
Allan L. Goldstein† and Hynda K. Kleinman
. Thymosin-β4 and thymosin β-4 derived peptides induce mast cell exocytosis
. Regenerative protein thymosin B-4 is a novel regulator
of purinergic signalling
Kevin W. Freeman,*,1 Brian R. Bowman,† and Bruce R. Zetter*,